Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Synaptogenix ( (SNPX) ) just unveiled an update.
On June 9, 2025, Synaptogenix, Inc. announced a Securities Purchase Agreement with accredited investors to raise $5.5 million through the sale of Series D convertible preferred stock and warrants. The company plans to use the proceeds for general corporate purposes and to acquire Bittensor TAO tokens as part of a new cryptocurrency treasury strategy. This move marks a significant shift in Synaptogenix’s operations, positioning it as a player in the AI and cryptocurrency sectors. The company also announced management changes, including the resignation of Dr. Daniel L. Alkon and Dr. Alan J. Tuchman from their executive roles, and the appointment of Joshua Silverman as Executive Chairman.
The most recent analyst rating on (SNPX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Synaptogenix stock, see the SNPX Stock Forecast page.
More about Synaptogenix
Synaptogenix, Inc. operates in the biotechnology industry, focusing on the development of therapeutics for neurodegenerative diseases. The company is expanding its market focus to include digital asset management, particularly through the acquisition and management of AI-related cryptocurrencies.
Average Trading Volume: 12,550
Technical Sentiment Signal: Sell
Current Market Cap: $3.35M
Learn more about SNPX stock on TipRanks’ Stock Analysis page.